Search research articles
Contact Us
Filters
Showing results (91-100 of 101) with videos related to
Page
of 11
Sort By:
Haematologica
|
January 19, 2023
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitors
Gregory W Roloff, Frank Wen, Aubrianna Ramsland, et al.
Blood
|
May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study
Lori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances
|
May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement
Ibrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Transplantation and Cellular Therapy
|
June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances
|
March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
Hannah Lust, Liora M Schultz, Soyang Kwon, et al.
Blood Advances
|
June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Tamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Advances
|
October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Yannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances
|
August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Bone Marrow Transplantation
|
August 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, et al.
Page
of 11
Search research articles
Search
Showing results (91-100 of 101) with videos related to
Sort By:
Page
of 11
Haematologica
|
January 19, 2023
Clinical and molecular response of acute myeloid leukemia harboring non-canonical <i>FLT3</i> N676K driver mutations to contemporary FLT3 inhibitors
Gregory W Roloff, Frank Wen, Aubrianna Ramsland, et al.
Blood
|
May 19, 2026
Consensus Recommendations for CAR T-Cell Administration in Adult Acute Lymphoblastic Leukemia: a Modified Delphi Study
Lori Muffly, Noelle V Frey, Gregory W Roloff, et al.
Blood Advances
|
May 7, 2025
Outcomes of Brexucabtagene Autoleucel in Relapsed/Refractory Acute Lymphoblastic Leukemia Patients with CNS Involvement
Ibrahim N Muhsen, Gregory W Roloff, Rawan G Faramand, et al.
Transplantation and Cellular Therapy
|
June 27, 2026
Allogeneic Hematopoietic Cell Transplant Following Standard of Care Brexucabtagene Autoleucel (Brexu-cel) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): Results from the Real-World Outcomes Collaborative of CAR T in Adult ALL (ROCCA)
Rawan G Faramand, Amy Zhang, Gregory W Roloff, et al.
Blood Advances
|
March 24, 2025
Real-world outcomes for young adult patients receiving CD19 CAR T-cell therapy
Hannah Lust, Liora M Schultz, Soyang Kwon, et al.
Blood Advances
|
June 25, 2026
Improved Outcomes with TKI Maintenance Following Brexucabtagene Autoleucel in Philadelphia-chromosome ALL
Tamer Othman, Gregory W Roloff, Katharine Miller, et al.
Blood Advances
|
October 6, 2025
CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia
Yannis K Valtis, Chenyu Lin, David Nemirovsky, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 17, 2024
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL
Gregory W Roloff, Ibrahim Aldoss, Noam E Kopmar, et al.
Blood Advances
|
August 2, 2024
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, et al.
Bone Marrow Transplantation
|
August 23, 2025
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Timothy E O'Connor, Chenyu Lin, Gregory W Roloff, et al.
Page
of 11